In my opinion, psychedelics will be widely used in the future to treat mental health disorders, from PTSD to depression - a thread on one of my favorite companies in the space $MMEDF

First, a little on the history of psychedelics. After the end of the initial research period that lasted from the 1950s-1970s, most psychedelic substances were classified as “drugs of abuse” with no recognized medical value

Bc of this, they were banned in the US, Canada, and Europe, especially after they took off among the counter culture. Efforts were made to develop selective serotonin reuptake inhibitors (SSRIs) but ultimately they failed to treat mental illness and caused serious side effects

Due to the lack of advancement, a US non-profit called the multidisciplinary association for psychedelic studies (MAPS) took action into their own hands and got approval from the FDA in the 1990s to begin researching psychedelics once again

This led to a revival in psychedelic research and now we are seeing those efforts finally starting paying off. The “psychedelic renaissance” is now entering a new stage, with a series of groundbreaking positive results gracing the pages of leading journals and clinical trials

The substantial progress for treating mental illnesses such as addiction, depression, anxiety and PTSD is extremely exciting. Some results can be found below

History out of the way, what does the market look like? The estimated TAM for psychedelics is an estimated $100B, with addiction, depression, anxiety and ADHD totaling roughly ~$60B

I think it’s universally accepted that we have a mental health crisis, yet we still have no clear links between psychiatric diagnoses and what’s going on in the brain – and no effective new classes of drugs. A solution for this market could be massive

So how can Mind Med capitalize on this? Well, they are leading psychedelic medicine biotech company that discovers, develops, and deploys psychedelic-inspired medicines that are primarily focused on mental illness

They currently have the broadest and most diversified pipeline of psychedelic drugs in clinical development and R&D, with 13 phase 1 trials complete and 3 phase 2 trials in progress

These are regulated clinical trials which provide them a mass amount of data which they can use for R&D. On this point, the FDA does have a clear regulatory framework and commercialization pathway

So what do they currently have included in their pipeline? They have a handful of exciting programs in the works, some of which have important milestones coming up next year

In the 2nd half of 2021, they plan on opening a pre-approved FDA investigational new drug (IND) application for their lead program, Lucy, which focuses on LSD therapy for anxiety disorders

Along with Lucy, they have another project called Layla that focuses on addiction treatment for opioids. The preliminary data from the study has shown that the drug is safe and well-tolerated. The doses tested to date have had no serious side effects

In addition to their existing pipeline, they are currently collaborating with leading psychedelic researchers like the Liecthi Lab at the University of Basel in Switzerland, a lab that has 10+ yrs of research and data on the benefits of psychedelics

Along with this partnership, they have proprietary tech that gives them exclusive global commercial rights

So summing all this up they have:
- Clinical trials for developing psychedelic medicine that could help with various mental illnesses
- Partnerships with leading psychedelic researchers
- A regulated FDA approval framework to comply with and follow
- Protectable IP

Another interesting note is that pharma companies are already trying to enter the space because they are beginning to realize the importance of psychedelic treatments

Lot’s of potential here if you ask me. To finish things off, let’s take a quick look at their management and financials

Management looks strong as they all have extensive experience in the biopharma and drug discovery space. One of their founders and co-CEO, JR Rahn used to be a silicon valley tech exec that can help them execute on their growth plans given his previous experience

I couldn’t find much on their financials but I was able to find this:
- Ending October 2020 they had cash reserves of $38M to enable continued progress of their clinical trial pipeline of psychedelic inspired medicines and experimental therapies

One last note, they do trade on the OTC markets (which I usually avoid) but they already applied to be listed on the NASDAQ. If it is approved and listed this year, it could be a catalyst for an increase in their share price due to more exposure and higher trading volume

All in all, $MMEDF is a leader in the development of psychedelic treatments for various mental diseases. As with many bio tech companies, there is a risk they fail to execute but in my opinion, if they do execute, the potential alone is too hard to pass up

@richard_chu97
@TerraPharma1
@Pharmdca

Quick thread on $MMEDF - one of the leading players in psychedelic treatments and medicine